513 related articles for article (PubMed ID: 7964965)
1. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
J Clin Oncol; 1994 Nov; 12(11):2471-508. PubMed ID: 7964965
[TBL] [Abstract][Full Text] [Related]
2. American Society of Clinical Oncology guidelines for the use of hematopoietic colony-stimulating factors.
Ozer H
Curr Opin Hematol; 1996 Jan; 3(1):3-10. PubMed ID: 9372045
[TBL] [Abstract][Full Text] [Related]
3. Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology.
Bennett CL; Weeks JA; Somerfield MR; Feinglass J; Smith TJ
J Clin Oncol; 1999 Nov; 17(11):3676-81. PubMed ID: 10550166
[TBL] [Abstract][Full Text] [Related]
4. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
5. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
6. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
7. Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology.
Bennett CL; Smith TJ; Weeks JC; Bredt AB; Feinglass J; Fetting JH; Hillner BE; Somerfield MR; Winn RJ
J Clin Oncol; 1996 Sep; 14(9):2511-20. PubMed ID: 8823330
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of colony-stimulating factors in acute leukemia.
Holdsworth MT; Mathew P
Ann Pharmacother; 2001 Jan; 35(1):92-108. PubMed ID: 11197591
[TBL] [Abstract][Full Text] [Related]
9. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
Smith TJ; Khatcheressian J; Lyman GH; Ozer H; Armitage JO; Balducci L; Bennett CL; Cantor SB; Crawford J; Cross SJ; Demetri G; Desch CE; Pizzo PA; Schiffer CA; Schwartzberg L; Somerfield MR; Somlo G; Wade JC; Wade JL; Winn RJ; Wozniak AJ; Wolff AC
J Clin Oncol; 2006 Jul; 24(19):3187-205. PubMed ID: 16682719
[TBL] [Abstract][Full Text] [Related]
10. Colony-stimulating factors as an adjunct to chemotherapy in small cell lung cancer.
Urban T; Schuller MP; Lebeau B
Eur Respir J; 1996 Mar; 9(3):596-602. PubMed ID: 8730024
[TBL] [Abstract][Full Text] [Related]
11. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.
Lyman GH
J Natl Compr Canc Netw; 2005 Jul; 3(4):557-71. PubMed ID: 16038646
[TBL] [Abstract][Full Text] [Related]
12. The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.
Liang DC
Paediatr Drugs; 2003; 5(10):673-84. PubMed ID: 14510625
[TBL] [Abstract][Full Text] [Related]
13. Colony-stimulating factors in the management of neutropenia and its complications.
Heuser M; Ganser A
Ann Hematol; 2005 Oct; 84(11):697-708. PubMed ID: 16047204
[TBL] [Abstract][Full Text] [Related]
14. Evidence-based use of colony-stimulating factors in elderly cancer patients.
Lyman GH; Kuderer N; Agboola O; Balducci L
Cancer Control; 2003; 10(6):487-99. PubMed ID: 14652525
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity.
Johnston EM; Crawford J
Semin Oncol; 1998 Oct; 25(5):552-61. PubMed ID: 9783594
[TBL] [Abstract][Full Text] [Related]
16. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.
Lyman GH; Kuderer NM
Crit Rev Oncol Hematol; 2004 May; 50(2):129-46. PubMed ID: 15157662
[TBL] [Abstract][Full Text] [Related]
17. [Prevention and treatment of febrile neutropenia].
Montemurro F; Gallicchio M; Aglietta M
Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
[TBL] [Abstract][Full Text] [Related]
18. Balancing the benefits and costs of colony-stimulating factors: a current perspective.
Lyman GH
Semin Oncol; 2003 Aug; 30(4 Suppl 13):10-7. PubMed ID: 14508715
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
20. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.
Smith TJ; Bohlke K; Lyman GH; Carson KR; Crawford J; Cross SJ; Goldberg JM; Khatcheressian JL; Leighl NB; Perkins CL; Somlo G; Wade JL; Wozniak AJ; Armitage JO;
J Clin Oncol; 2015 Oct; 33(28):3199-212. PubMed ID: 26169616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]